Source comparison
Is CJC-1295 Safe Side Effects: Comparison Across GH Secretagogues
CJC-1295 DAC 6–8 days Water retention, joint stiffness, injection site reactions Moderate (receptor downregulation after 12+ weeks continuous use) Best for researchers prioritizing dosing convenience; requires cycling to preserve efficacy CJC-1295 No DAC (Mod
This comparison does not assign a generated winner or score.
- CJC-1295 DAC
- 6–8 days
- Water retention, joint stiffness, injection site reactions
- Moderate (receptor downregulation after 12+ weeks continuous use)
- Best for researchers prioritizing dosing convenience; requires cycling to preserve efficacy
- CJC-1295 No DAC (Mod GRF 1-29)
- 30 minutes
- Transient flushing, mild headache, injection site reactions
- Low (pulsatile pattern preserves receptor sensitivity)
- Best for researchers prioritizing natural GH rhythm; requires multiple daily doses
- Ipamorelin
- 2 hours
- Minimal; occasional mild headache or transient hunger
- Very low (ghrelin mimetic with high receptor selectivity)
- Often stacked with CJC-1295 to amplify GH pulse without additive side effects
- GHRP-2
- 20 minutes
- Pronounced hunger, cortisol/prolactin elevation at high doses
- Low to moderate
- Effective GH secretagogue but cortisol spike limits appeal for metabolic research
- Hexarelin
- 70 minutes
- Water retention, significant cortisol elevation, desensitization within 2–4 weeks
- High (rapid tachyphylaxis)
- Potent but impractical for protocols >4 weeks; cortisol elevation is a limiting factor
- The table underscores a critical point: CJC-1295's side effect profile is moderate relative to other growth hormone secretagogues, but durability matters. Peptides like hexarelin produce faster desensitization, while ipamorelin offers cleaner pharmacology but weaker GH pulses. Researchers combining CJC-1295 with ipamorelin exploit synergistic GH release with minimal additive side effects. A strategy supported by research showing that GHRH analogs and ghrelin mimetics act on distinct receptor pathways, allowing additive efficacy without compounding adverse events.